|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ovarian Neoplasms | |||||
| Peritoneal Neoplasms | |||||
| Fallopian Tube Neoplasms | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Abdominal Neoplasms | |||||
| Adnexal Diseases | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Fallopian Tube Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Peritoneal Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| CP-547,632 | |||||
| 5 | Sponsors listed in this trial | ||||
| Pfizer | |||||